Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common spice boost liver health in fatty liver disease?

NCT ID NCT07768657

Disease control Sponsor: University of Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial tests whether adding sumac spice to a calorie-restricted diet can improve liver function and metabolic health in adults with obesity and non-alcoholic fatty liver disease (NAFLD). About 100 participants aged 30-60 will be randomly assigned to take either a placebo or one of two doses of sumac daily for 12 weeks. Researchers will measure changes in liver enzymes, blood sugar, insulin resistance, cholesterol, and inflammation to see if sumac offers extra benefits beyond diet alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sumac (Rhus coriaria L.) supplement at 1.5 g/day or 3.0 g/day, combined with a calorie-restricted diet (1250-1300 kcal/day) for 12 weeks.
What this could lead to
If sumac proves effective, it could offer a natural, low-cost addition to diet plans for improving liver function and metabolic health in people with fatty liver disease.
What could go wrong
This is a small, early-stage trial, and results may not be conclusive. The benefits of sumac beyond calorie restriction alone are uncertain, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

102 people

The number who actually took part.

Started

Jun 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * subjects were required to be obese adults aged 30 to 60 years with a Body Mass Index (BMI) of 30 kg/m2 * confirmed diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) via abdominal ultrasonography. * Biochemically, participants met the criteria for elevated liver enzymes, defined as alanine aminotransferase (ALT) \> 56 U/L, aspartate aminotransferase (AST) \> 40 U/L, or alkaline phosphatase (ALP) \> 147 U/L. * They also exhibited impaired glycemic status with a fasting blood sugar (FBS) \> 130 mg/dL and a glycated hemoglobin (HbA1c) level between 6.0% and 8.0%, . * dyslipidemia characterized by total cholesterol \>200 mg/dL, triglycerides \>150 mg/dL low-density lipoprotein (LDL) \>100 mg/dL, or high-density lipoprotein (HDL) \< 40 mg/dL. * Finally, all selected individuals demonstrated a documented willingness to participate in a supervised, calorie-restricted dietary intervention. Exclusion Criteria: * individuals were excluded from the study if they presented with secondary causes of hepatic steatosis, including significant alcohol consumption, chronic viral hepatitis (B or C), * autoimmune hepatitis, or drug-induced liver injury. * Potential participants were also excluded if they had a history of advanced liver disease (cirrhosis or hepatocellular carcinoma), * severe renal or cardiovascular comorbidities, or were currently taking medications known to induce steatosis (such as systemic corticosteroids or amiodarone). .Pregnant or lactating women were likewise excluded from enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glucose are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glucose Insulin Lipid profile Liver biomarkers

Contacts and locations

Locations

  • Sana Noreen

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.